Registry of Guardant360® Use and Outcomes In People With Advanced Cancer Read more about Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) Read more about A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Read more about To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer Read more about Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer Read more about Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer Read more about VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) Read more about Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Read more about A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) Read more about A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)